PSNL News and Press, Personalis Inc. From 03/02/23

Personalis ( NASDAQ: PSNL ) on Thursday said the company appointed Christopher Hall as CEO and a member of the board, effective immediately. Hall will become CEO in addition to his role as president. Hall joined Personalis in October 2022 and became presiden...

New Leadership Structure Supports Strategic Objectives to Drive New Paradigm in Cancer Management and Lead in Minimal Residual Disease Testing Aaron Tachibana Promoted to COO and Dr. Richard Chen to EVP, R&D Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for ...

Personalis, Inc. (PSNL) Q4 2022 Results Conference Call February 23, 2023 05:00 PM ET Company Participants Caroline Corner - Investor Relations Aaron Tachibana - Interim Chief Financial Officer and Chief Financial Officer Chris Hall - President Rich Chen - Chief Me...

Personalis press release ( NASDAQ: PSNL ): Q4 GAAP EPS of -$0.67 misses by $0.03 . Revenue of $16.7M (-19.2% Y/Y) beats by $0.45M . Sees Q1 2023 total company revenue of approximately $17.5 million. The consensus estimate is $21.90M. Sees FY 2023 total company ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided recent business highlights. Recent Business Highlights Announced a continuing partnershi...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023. In conjunction with the release, Personalis will host a conference call and webcast t...

The shares of Personalis, Inc. ( NASDAQ: PSNL ) gained for the fifth straight session on Monday after Needham upgraded the cancer genomics company to Buy from Hold, arguing that stock is “significantly undervalued” despite the recent gains. Personalis ( PSNL ) has mo...

Main Tips for Buying Penny Stocks Right Now Penny stocks have been a popular investment option for many years, offering the potential for high returns at a relatively low cost. With the stock market constantly fluctuating, penny stocks can offer a great opportunity for those looking to ma...

Personalis ( NASDAQ: PSNL ) and Moderna ( NASDAQ: MRNA ) said they had signed a new agreement to continue using the PSNL's NeXT Platform as part of upcoming clinical studies testing cancer vaccine mRNA-4157/V940, jointly developed by Moderna and Merck ( MRK ). The plat...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis Ne...